Ipilimumab-话题@MedSci

#Ipilimumab#

50篇内容 | 2508人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1365764, encodeId=53751365e64f8, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=晚期肝细胞癌：Cabozantinib、Nivolumab和Ipilimumab的三联疗法具有显著优势, objectType=article, longId=186743, objectId=96bb186e4389, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96bb186e4389, replyNumber=0, likeNumber=49, createdTime=2020-01-27, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96bb186e4389, moduleTitle=晚期肝细胞癌：Cabozantinib、Nivolumab和Ipilimumab的三联疗法具有显著优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96bb186e4389)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365763, encodeId=17141365e6315, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=J Clin Oncol：III期试验：Ipilimumab辅助疗法与大剂量干扰素α-2b用于高风险黑色素瘤的优劣对比, objectType=article, longId=185702, objectId=43a9185e0237, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43a9185e0237, replyNumber=0, likeNumber=72, createdTime=2020-01-06, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43a9185e0237, moduleTitle=J Clin Oncol：III期试验：Ipilimumab辅助疗法与大剂量干扰素α-2b用于高风险黑色素瘤的优劣对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43a9185e0237)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365762, encodeId=10ab1365e62c7, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=NEJM：Nivolumab + ipilimumab一线治疗非小细胞肺癌, objectType=article, longId=183382, objectId=556b183382e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=556b183382e6, replyNumber=0, likeNumber=85, createdTime=2019-11-23, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=556b183382e6, moduleTitle=NEJM：Nivolumab + ipilimumab一线治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=556b183382e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365761, encodeId=a88f1365e61e7, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=2019 CSCO：CS1002的I期试验证明其特性可与ipilimumab媲美, objectType=article, longId=179913, objectId=e63f1e991360, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e63f1e991360, replyNumber=0, likeNumber=67, createdTime=2019-09-25, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e63f1e991360, moduleTitle=2019 CSCO：CS1002的I期试验证明其特性可与ipilimumab媲美, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e63f1e991360)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365760, encodeId=f7d41365e60d0, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=CTLA4单抗ipilimumab和PD-1单抗nivolumab联合的临床研究证实：该药物组合对晚期肾细胞癌患有明显治疗优势, objectType=article, longId=166310, objectId=318316631011, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=318316631011, replyNumber=0, likeNumber=62, createdTime=2019-05-20, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=318316631011, moduleTitle=CTLA4单抗ipilimumab和PD-1单抗nivolumab联合的临床研究证实：该药物组合对晚期肾细胞癌患有明显治疗优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=318316631011)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365759, encodeId=52381365e591e, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=Opdivo（nivolumab）联合Yervoy（ipilimumab）具有转移性去势抵抗性前列腺癌患者的治疗希望, objectType=article, longId=160343, objectId=61541603433f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61541603433f, replyNumber=0, likeNumber=55, createdTime=2019-02-20, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61541603433f, moduleTitle=Opdivo（nivolumab）联合Yervoy（ipilimumab）具有转移性去势抵抗性前列腺癌患者的治疗希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61541603433f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365758, encodeId=1d3c1365e58f3, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=JCO：Nivolumab和Nivolumab联合Ipilimumab治疗转移性食管胃癌患者, objectType=article, longId=147192, objectId=187c14e1923f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=187c14e1923f, replyNumber=0, likeNumber=76, createdTime=2018-08-23, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=187c14e1923f, moduleTitle=JCO：Nivolumab和Nivolumab联合Ipilimumab治疗转移性食管胃癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=187c14e1923f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365757, encodeId=73601365e57f0, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=CLIN CANCER RES：Ipilimumab治疗低甲基化治疗失败的骨髓增生异常综合征患者, objectType=article, longId=146599, objectId=3dd2146599e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dd2146599e1, replyNumber=0, likeNumber=66, createdTime=2018-08-15, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dd2146599e1, moduleTitle=CLIN CANCER RES：Ipilimumab治疗低甲基化治疗失败的骨髓增生异常综合征患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dd2146599e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365756, encodeId=f37b1365e568d, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=CLIN CANCER RES：Pembrolizumab联合聚乙二醇干扰素或Ipilimumab治疗晚期黑色素瘤或肾细胞癌, objectType=article, longId=136477, objectId=7a5f1364e7eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a5f1364e7eb, replyNumber=0, likeNumber=76, createdTime=2018-04-27, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a5f1364e7eb, moduleTitle=CLIN CANCER RES：Pembrolizumab联合聚乙二醇干扰素或Ipilimumab治疗晚期黑色素瘤或肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a5f1364e7eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365755, encodeId=096c1365e555c, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=EUR J Cancer：ipilimumab在NY-ESO-1阳性黑色素瘤患者中的作用, objectType=article, longId=131023, objectId=c06d1310231d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c06d1310231d, replyNumber=0, likeNumber=60, createdTime=2018-03-02, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c06d1310231d, moduleTitle=EUR J Cancer：ipilimumab在NY-ESO-1阳性黑色素瘤患者中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c06d1310231d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365754, encodeId=c66b1365e54b9, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=EUR J Cancer：外周血CD8效应记忆T细胞与ipilimumab治疗的IV期黑素瘤结果具有相关性, objectType=article, longId=125224, objectId=41c6125224e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41c6125224e5, replyNumber=0, likeNumber=55, createdTime=2018-01-02, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41c6125224e5, moduleTitle=EUR J Cancer：外周血CD8效应记忆T细胞与ipilimumab治疗的IV期黑素瘤结果具有相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41c6125224e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365753, encodeId=83e31365e5380, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=CLIN CANCER RES：接受新辅助化疗联合Ipilimumab治疗的早期非小细胞肺癌患者免疫激活, objectType=article, longId=123732, objectId=0f2d123e3257, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f2d123e3257, replyNumber=0, likeNumber=60, createdTime=2017-12-19, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f2d123e3257, moduleTitle=CLIN CANCER RES：接受新辅助化疗联合Ipilimumab治疗的早期非小细胞肺癌患者免疫激活, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f2d123e3257)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365752, encodeId=9d481365e526e, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=治疗黑色素瘤 Opdivo®(Nivolumab)疗效优于Yervoy®(Ipilimumab), objectType=article, longId=122648, objectId=9aba12264896, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9aba12264896, replyNumber=0, likeNumber=58, createdTime=2017-12-09, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9aba12264896, moduleTitle=治疗黑色素瘤 Opdivo®(Nivolumab)疗效优于Yervoy®(Ipilimumab), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9aba12264896)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365751, encodeId=97d01365e510a, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=JAMA：Ipilimumab对于人乳头瘤相关的转移或复发性宫颈癌疗效如何？, objectType=article, longId=121085, objectId=c15d121085ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c15d121085ce, replyNumber=0, likeNumber=77, createdTime=2017-11-24, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c15d121085ce, moduleTitle=JAMA：Ipilimumab对于人乳头瘤相关的转移或复发性宫颈癌疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c15d121085ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365750, encodeId=907b1365e5008, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=NEJM：III-IV期黑色素瘤患者术后辅助治疗——Nivolumab vs Ipilimumab, objectType=article, longId=119406, objectId=75a6119406be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75a6119406be, replyNumber=0, likeNumber=71, createdTime=2017-11-11, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75a6119406be, moduleTitle=NEJM：III-IV期黑色素瘤患者术后辅助治疗——Nivolumab vs Ipilimumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75a6119406be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365749, encodeId=abf91365e49c9, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=NEJM：晚期黑色素瘤患者的治疗是nivolumab联合ipilimumab治疗还是单独用药？, objectType=article, longId=115359, objectId=277f115359bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=277f115359bb, replyNumber=0, likeNumber=81, createdTime=2017-10-09, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=277f115359bb, moduleTitle=NEJM：晚期黑色素瘤患者的治疗是nivolumab联合ipilimumab治疗还是单独用药？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=277f115359bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365748, encodeId=77951365e4880, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=JCO ：Nivolumab+Ipilimumab联合治疗黑色素瘤的疗效和安全性研究, objectType=article, longId=111056, objectId=508e111056bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=508e111056bc, replyNumber=0, likeNumber=110, createdTime=2017-08-29, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=508e111056bc, moduleTitle=JCO ：Nivolumab+Ipilimumab联合治疗黑色素瘤的疗效和安全性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=508e111056bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365747, encodeId=30841365e4718, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=Lancet：Pembrolizumab与Ipilimumab用于晚期黑色素瘤的疗效对比。, objectType=article, longId=109075, objectId=1fa71090e54d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fa71090e54d, replyNumber=0, likeNumber=97, createdTime=2017-08-18, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fa71090e54d, moduleTitle=Lancet：Pembrolizumab与Ipilimumab用于晚期黑色素瘤的疗效对比。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fa71090e54d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365746, encodeId=973e1365e46cc, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=JCO：Nivolumab联合ipilimumab——转移性肾细胞癌患者的新福音？, objectType=article, longId=105941, objectId=f13c1059413a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f13c1059413a, replyNumber=0, likeNumber=83, createdTime=2017-07-20, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f13c1059413a, moduleTitle=JCO：Nivolumab联合ipilimumab——转移性肾细胞癌患者的新福音？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f13c1059413a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365745, encodeId=6b0f1365e4529, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=JCO：Nivolumab联合Ipilimumab治疗转移性肾细胞癌, objectType=article, longId=105041, objectId=ab6110504191, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab6110504191, replyNumber=0, likeNumber=76, createdTime=2017-07-11, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab6110504191, moduleTitle=JCO：Nivolumab联合Ipilimumab治疗转移性肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab6110504191)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Ipilimumab

2020-05-29

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

晚期肝细胞癌：Cabozantinib、Nivolumab和Ipilimumab的三联疗法具有显著优势

2020-01-27

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

J Clin Oncol：III期试验：Ipilimumab辅助疗法与大剂量干扰素α-2b用于高风险黑色素瘤的优劣对比

2020-01-06

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

NEJM：Nivolumab + ipilimumab一线治疗非小细胞肺癌

2019-11-23

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

2019 CSCO：CS1002的I期试验证明其特性可与ipilimumab媲美

2019-09-25

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

CTLA4单抗ipilimumab和PD-1单抗nivolumab联合的临床研究证实：该药物组合对晚期肾细胞癌患有明显治疗优势

2019-05-20

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

Opdivo（nivolumab）联合Yervoy（ipilimumab）具有转移性去势抵抗性前列腺癌患者的治疗希望

2019-02-20

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

JCO：Nivolumab和Nivolumab联合Ipilimumab治疗转移性食管胃癌患者

2018-08-23

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

CLIN CANCER RES：Ipilimumab治疗低甲基化治疗失败的骨髓增生异常综合征患者

2018-08-15

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

CLIN CANCER RES：Pembrolizumab联合聚乙二醇干扰素或Ipilimumab治疗晚期黑色素瘤或肾细胞癌

2018-04-27

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

EUR J Cancer：ipilimumab在NY-ESO-1阳性黑色素瘤患者中的作用

2018-03-02

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

EUR J Cancer：外周血CD8效应记忆T细胞与ipilimumab治疗的IV期黑素瘤结果具有相关性

2018-01-02

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

CLIN CANCER RES：接受新辅助化疗联合Ipilimumab治疗的早期非小细胞肺癌患者免疫激活

2017-12-19

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

治疗黑色素瘤 Opdivo®(Nivolumab)疗效优于Yervoy®(Ipilimumab)

2017-12-09

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

JAMA：Ipilimumab对于人乳头瘤相关的转移或复发性宫颈癌疗效如何？

2017-11-24

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

NEJM：III-IV期黑色素瘤患者术后辅助治疗——Nivolumab vs Ipilimumab

2017-11-11

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

NEJM：晚期黑色素瘤患者的治疗是nivolumab联合ipilimumab治疗还是单独用药？

2017-10-09

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

JCO ：Nivolumab+Ipilimumab联合治疗黑色素瘤的疗效和安全性研究

2017-08-29

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

Lancet：Pembrolizumab与Ipilimumab用于晚期黑色素瘤的疗效对比。

2017-08-18

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

JCO：Nivolumab联合ipilimumab——转移性肾细胞癌患者的新福音？

2017-07-20

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

JCO：Nivolumab联合Ipilimumab治疗转移性肾细胞癌

2017-07-11

科室
- - 订阅+
  - 更多科室
工具
服务